Cargando…

Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors

Accumulating clinical evidence suggests that adoptive T-cell immunotherapy could be a promising option for control of cancer; evident examples include the graft-vs-leukemia effect mediated by donor lymphocyte infusion (DLI) and therapeutic infusion of ex vivo-expanded tumor-infiltrating lymphocytes...

Descripción completa

Detalles Bibliográficos
Autor principal:	Fujiwara, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276906/ https://www.ncbi.nlm.nih.gov/pubmed/25517545 http://dx.doi.org/10.3390/ph7121049

Ejemplares similares

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies
por: Ye, Baixin, et al.
Publicado: (2017)

T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies
por: Janelle, Valérie, et al.
Publicado: (2020)

Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia
por: Ochi, Toshiki, et al.
Publicado: (2010)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies
por: Pont, M. J., et al.
Publicado: (2016)

A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy
por: Casey, Nicholas Paul, et al.
Publicado: (2016)

Chimeric antigen T cell receptor treatment in hematological malignancies
por: Ali, Natasha
Publicado: (2019)

Cytotoxicity of WT1-reactive T cells against Wilms tumor: An implication for antigen-specific adoptive immunotherapy
por: Monzavi, Seyed Mostafa, et al.
Publicado: (2023)

Cellular immunotherapy for refractory hematological malignancies
por: Reagan, John L, et al.
Publicado: (2013)

Therapeutic Advances in Immunotherapies for Hematological Malignancies
por: Nogami, Ayako, et al.
Publicado: (2022)

Editorial: Immunotherapy for hematological malignancies in children
por: Zhou, Yusi, et al.
Publicado: (2023)

Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies
por: Yan, Weiqi, et al.
Publicado: (2020)

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2020)

Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects
por: Shi, Huan, et al.
Publicado: (2014)

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
por: Lin, Wen-Ying, et al.
Publicado: (2020)

Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies
por: Shen, Chunyi, et al.
Publicado: (2020)

Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
por: Yang, Zhihuan, et al.
Publicado: (2023)

Advent of CRISPR Based Immunotherapy in Hematologic Malignancies
por: Perez, RK, et al.
Publicado: (2018)

Immunotherapy in hematologic malignancies: past, present, and future
por: Im, Annie, et al.
Publicado: (2017)

NK Cell-Based Immunotherapy for Hematological Malignancies
por: Sivori, Simona, et al.
Publicado: (2019)

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19
por: Monzavi, Seyed Mostafa, et al.
Publicado: (2021)

New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology
por: Gunduz, Mehmet, et al.
Publicado: (2021)

Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies
por: Zhao, Dong, et al.
Publicado: (2023)

Expression of aberrant antigens in hematological malignancies: A single center experience
por: Shahni, Aneeta, et al.
Publicado: (2018)

Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy
por: Gillis, John Stuart
Publicado: (2006)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022)

Cellular immunotherapy as a beacon of hope for hematological malignancies
por: Lee, Hyun-Ju, et al.
Publicado: (2015)

Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
por: Noh, Ji-Yoon, et al.
Publicado: (2020)

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
por: Tang, Lu, et al.
Publicado: (2023)

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
por: Keshavarz, Ali, et al.
Publicado: (2022)

Semaphorins and Their Receptors in Hematological Malignancies
por: Wei, Li, et al.
Publicado: (2019)

Ferroptosis in hematological malignant tumors
por: Liu, Yong, et al.
Publicado: (2023)

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies
por: Guo, Zhenling, et al.
Publicado: (2021)

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience
por: Sun, Wei, et al.
Publicado: (2023)

Antigen-specific T cells conditioned with MDSC display a surprising increased anti-tumor activity after adoptive T cell-based immunotherapy
por: Raber, Patrick, et al.
Publicado: (2015)

Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective
por: Allegra, Alessandro, et al.
Publicado: (2021)

Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
por: Xu, Zhengli, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pqet0geviflh0uvmdjrce561d0